Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors

doi:10.1177/1010428317706211

科研成果详情

题名	Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors
作者	Zheng, Zhen 1; Xie, Deyao2; Su, Huafang1; Lin, Baochai1; Zhao, Lihao1; Deng, Xia1; Chen, Hanbin 1; Fei, Shaoran 1; Jin, Xiance1; Xie, Congying1
发表日期	2017-06-15
发表期刊	TUMOR BIOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Non-small-cell lung cancer malignant pleural effusion epidermal growth factor receptor tyrosine kinase inhibitors progression-free survival
其他关键词	GROWTH-FACTOR RECEPTOR ; ADENOCARCINOMA ; CHEMOTHERAPY ; EFFICACY ; RESISTANCE ; THERAPY
摘要	Recent studies demonstrated a significantly increased frequency of epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) patients with malignant pleural effusions (MPEs). The purpose of this study is to investigate the effect of first-line and second-line EGFR-tyrosine kinase inhibitors (TKIs) in the treatment of NSCLC with MPEs harboring exon 19 deletion and L858R mutation. From 2010 to 2015, 203 NSCLC patients with MPEs harboring EGFR mutation treated with EGFR-TKIs were reviewed. The efficacy were evaluated with Pearson chi-square or Fisher's exact tests, Log-rank test and Cox proportional hazards model. The objective response rate (ORR) and disease control rate (DCR) for patients treated with first-line and second-line EGFR-TKIs were 21.9%, 91.4% and 14.7%, 85.3%, respectively. The overall median PFS and OS of enrolled NSCLC patients with MPE were 9.3 months (95% CI, 8.4-10.2 months), 20.9 months (95% CI, 18.9-22.9 months) after first-line TKIs, and 7.6 months (95% CI, 6.6-8.6 months), 15.3 months (95% CI, 13.6-15.9 months) after second-line TKIs. The exon 19 deletion arm had a longer median PFS (9.4 vs 7.1 months, p=0.003) and OS (16.8 vs 13.8 months, p=0.003) compared with the L858R mutation arm after second-line TKIs. In a conclusion, EGFR genotype was an independent predictor of PFS and OS. No significant side effects differences between the two mutation groups was observed for first or second-line EGFR-TKIs. This study demonstrated that EGFR mutations are significant predictors for advanced NSCLC patients with MPE receiving second-line EGFR-TKIs treatment.
资助项目	Wenzhou Municipal Science and Technology Bureau [H20100068]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [11675122]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LY16H160047, LY17H160051]
出版者	SAGE PUBLICATIONS LTD
出版地	LONDON
ISSN	1010-4283
EISSN	1423-0380
卷号	39 期号:6
DOI	10.1177/1010428317706211
页数	8
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000403602900001
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	28618947
SCOPUSEID	2-s2.0-85025150188
通讯作者地址	[Xie, Congying]Department of Radiotherapy and Chemotherapy,The First Affiliated Hospital of Wenzhou Medical University,No. 2 Fuxue Lane,Wenzhou,325000,China
Scopus学科分类	Cancer Research
引用统计	被引频次：6[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/19354
专题	附属第一医院_放化疗科附属第一医院_心胸外科
通讯作者	Xie, Congying
作者单位	1.Department of Radiotherapy and Chemotherapy,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 2.Department of Thoracic Surgery,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China
第一作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
通讯作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Zheng, Zhen,Xie, Deyao,Su, Huafang,et al. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors[J]. TUMOR BIOLOGY,2017,39(6).
APA	Zheng, Zhen., Xie, Deyao., Su, Huafang., Lin, Baochai., Zhao, Lihao., ... & Xie, Congying. (2017). Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors. TUMOR BIOLOGY, 39(6).
MLA	Zheng, Zhen,et al."Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors".TUMOR BIOLOGY 39.6(2017).